Azole Antifungal Resistance in Candida albicans and Emerging Non- albicans Candida Species

Within the limited antifungal armamentarium, the azole antifungals are the most frequent class used to treat infections. Azole antifungals such as fluconazole are often preferred treatment for many infections as they are inexpensive, exhibit limited toxicity, and are available for oral administratio...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 7; p. 2173
Main Authors Whaley, Sarah G, Berkow, Elizabeth L, Rybak, Jeffrey M, Nishimoto, Andrew T, Barker, Katherine S, Rogers, P David
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 12.01.2017
Subjects
Microbiology
Candida albicans
antifungal
Candida krusei
Candida tropicalis
Candida glabrata
resistance
Candida parapsilosis
azole
Online AccessGet full text

Cover

More Information
Summary:Within the limited antifungal armamentarium, the azole antifungals are the most frequent class used to treat infections. Azole antifungals such as fluconazole are often preferred treatment for many infections as they are inexpensive, exhibit limited toxicity, and are available for oral administration. There is, however, extensive documentation of intrinsic and developed resistance to azole antifungals among several species. As the frequency of azole resistant isolates in the clinical setting increases, it is essential to elucidate the mechanisms of such resistance in order to both preserve and improve upon the azole class of antifungals for the treatment of infections. This review examines azole resistance in infections caused by as well as the emerging non- species , and and in particular, describes the current understanding of molecular basis of azole resistance in these fungal species.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Miguel Cacho Teixeira, Universidade de Lisboa, Portugal; Siddharth Kaushal Tripathi, University of Mississippi, USA; Sudhanshu Shukla, Amity University of Haryana, India
Present Address: Elizabeth Berkow, Fungal Service Team, Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA
Edited by: Dominique Sanglard, University of Lausanne, Switzerland
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2016.02173